Wyeth Submits European Marketing Authorization Application For Its 13-Valent Vaccine For The Prevention Of Pneumococcal Disease

Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMEA) for approval to market its investigational 13-valent pneumococcal conjugate vaccine (PCV13) for infants and young children. Read more ...

RHEI Pharmaceuticals, Inc. announced that the final clinical trial for Tibozole, a locally active antifungal with low dose miconazole in a patented mucoadhesive system, has been initiated in China. This will be the last clinical trial conducted for submission of the New Drug Application (NDA) to the State Food and Drug Administration (SFDA) in China. RHEI licensed Tibozole from Tibotec, a Johnson and Johnson company. Read more ...

Newly formed consortium to advance eradication of inflammatory breast cancer.

The University of Texas M. D. Anderson Cancer Center will hold the first international inflammatory breast cancer (IBC) conference on December 6-7, to bring together internationally recognized breast cancer clinicians and scientists.

Participants will present new clinical discoveries and participate in educational workshops, with the goal of improving diagnosis and management of this rare but deadly disease.

read more

Read more ...

ASM Press announces publication of the latest volume in its popular series on new and emerging infectious diseases. Based on sessions at recent scientific conferences, Emerging Infections 8 offers up-to-date information and the most current research on new and emerging infections that have generated international interest. Read more ...